Mark A Quinn - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Mark A Quinn

Showing results (11-20 of 12) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 12 results.

Annals of the Rheumatic Diseases|November 28, 2006

Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approachZunaid Karim, Mark A Quinn, Richard J Wakefield, et al.

Arthritis and Rheumatism|January 11, 2005

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trialMark A Quinn, Philip G Conaghan, Philip J O'Connor, et al.

Pageof 2

Search research articles

Showing results (11-20 of 12) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 12 results.

Annals of the Rheumatic Diseases|November 28, 2006

Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approachZunaid Karim, Mark A Quinn, Richard J Wakefield, et al.

Arthritis and Rheumatism|January 11, 2005

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trialMark A Quinn, Philip G Conaghan, Philip J O'Connor, et al.

Pageof 2